Reena S. Cecchini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Reena S. Cecchini has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Patricia A. Ganz
David Geffen School of Medicine at UCLA, Los Angeles, CA
23 shared publications - Greg Yothers
Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA
21 shared publications - Norah Lynn Henry
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
19 shared publications - Ron D. Hays
Division of General Internal Medicine and Health Services Research, UCLA Department of Medicine, Los Angeles, USA
19 shared publications - Michael Luu
Biostatistics and Bioinformatics Core, Cedars-Sinai Medical Center, Los Angeles, CA
18 shared publications - Mourad Tighiouart
Biostatistics Shared Resource, Cedars-Sinai Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
18 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Table S2 provides information about the number of patients with missing adverse events at each timepoint for anastrozole treatment.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Table S2 provides information about the number of patients with missing adverse events at each timepoint for anastrozole treatment.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Table S1 outlines all predictors employed to predict treatment discontinuation, including the predictor variable name, variable description, variable type, and whether the data was collected over time or only at baseline.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Table S1 outlines all predictors employed to predict treatment discontinuation, including the predictor variable name, variable description, variable type, and whether the data was collected over time or only at baseline.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Table S3 provides information about the number of patients with missing adverse events at each timepoint for tamoxifen treatment.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Table S3 provides information about the number of patients with missing adverse events at each timepoint for tamoxifen treatment.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S2 shows the estimated discontinuation curves by training dataset and validation cohort for the anastrozole-treated patients.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S2 shows the estimated discontinuation curves by training dataset and validation cohort for the anastrozole-treated patients.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S7 presents a screenshot of the web tool; the supplementary data provides instructions for utilizing the web-based treatment discontinuation predictive tool developed based on the predictive survival models.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S7 presents a screenshot of the web tool; the supplementary data provides instructions for utilizing the web-based treatment discontinuation predictive tool developed based on the predictive survival models.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S6 (a) shows the actual eight PROs of patient 1 at two time points, baseline, and 6 months (shown by the black dotted line). This patient is also overweight at baseline (25 < BMI < 30). In the clinical data set, this patient discontinued treatment at 14 months, but this information was not used in the model. Supplementary Figure S6 (b) shows the estimated probability of treatment discontinuation for patient 1 anytime after 6 months but before 18 months. Supplementary Figure S6 (c) shows similar information for patient 2 who is also overweight. However, patient 2 completed treatment by 60 months. Supplementary Figure S6 (d) shows the estimated probability of treatment discontinuation for patient 2 anytime after 6 months but before 18 months.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S6 (a) shows the actual eight PROs of patient 1 at two time points, baseline, and 6 months (shown by the black dotted line). This patient is also overweight at baseline (25 < BMI < 30). In the clinical data set, this patient discontinued treatment at 14 months, but this information was not used in the model. Supplementary Figure S6 (b) shows the estimated probability of treatment discontinuation for patient 1 anytime after 6 months but before 18 months. Supplementary Figure S6 (c) shows similar information for patient 2 who is also overweight. However, patient 2 completed treatment by 60 months. Supplementary Figure S6 (d) shows the estimated probability of treatment discontinuation for patient 2 anytime after 6 months but before 18 months.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S2 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Methods S2 provides a statistical description of the prediction error used to assess the model performance.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S2 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Methods S2 provides a statistical description of the prediction error used to assess the model performance.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S5 illustrates the estimated time-dependent ROC curves using the PCCox and PCCox BLUP models in the validation cohort for tamoxifen treatment. The area under the ROC curve (AUC) and its corresponding 95% confidence interval for the four sets of s and tau are embedded within the plots.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S5 illustrates the estimated time-dependent ROC curves using the PCCox and PCCox BLUP models in the validation cohort for tamoxifen treatment. The area under the ROC curve (AUC) and its corresponding 95% confidence interval for the four sets of s and tau are embedded within the plots.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Methods S1 provides a comprehensive statistical description of the two applied predictive survival models (PC Cox model and PC Cox BLUP model).
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Methods S1 provides a comprehensive statistical description of the two applied predictive survival models (PC Cox model and PC Cox BLUP model).
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S3 shows the estimated discontinuation curves by training dataset and validation cohort for the tamoxifen-treated patients.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Supplementary Figure S3 shows the estimated discontinuation curves by training dataset and validation cohort for the tamoxifen-treated patients.